Aberdeen Group
CYTK icon

Aberdeen Group’s Cytokinetics CYTK Stock Holding History

Aberdeen Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
119,435
-363,839
-75% -$26.1M 0.01% 593
2026
Q1 		$31.9M Buy
483,274
+213
+0% +$13.5K 0.05% 299
2025
Q4 		$30.7M Sell
483,061
-444,771
-48% -$27.7M 0.05% 314
2025
Q3 		$51M Buy
927,832
+4,903
+0.5% +$202K 0.08% 201
2025
Q2 		$30.5M Buy
922,929
+320,508
+53% +$11.1M 0.05% 308
2025
Q1 		$24.2M Buy
602,421
+151,908
+34% +$6.98M 0.05% 345
2024
Q4 		$21.2M Buy
450,513
+102,457
+29% +$5.32M 0.04% 359
2024
Q3 		$18.4M Sell
348,056
-21,181
-6% -$1.18M 0.03% 404
2024
Q2 		$20M Buy
369,237
+129,995
+54% +$7.85M 0.04% 383
2024
Q1 		$16.8M Buy
239,242
+108,982
+84% +$8.43M 0.03% 442
2023
Q4 		$10.9M Buy
+130,260
New +$4.72M 0.02% 534

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group's CYTK Position: Q2 2026 in Review

Aberdeen Group reduced its Cytokinetics (CYTK) stake by 75% in Q2 2026, selling an estimated $26.1M and leaving 119,435 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #593.

Aberdeen Group first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. The position peaked at $51M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Aberdeen Group held 119,435 shares of Cytokinetics worth $10.2M as of Q2 2026.
  • Aberdeen Group sold 363,839 Cytokinetics shares in Q2 2026, an estimated $26.1M.
  • Cytokinetics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #593 holding.
  • Aberdeen Group first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • Aberdeen Group's Cytokinetics position peaked at $51M in Q3 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.